Breast Sentinel Lymph Node Dissection Before Preoperative Chemotherapy | Oncology | JAMA Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
1.
Giuliano  AEKirgan  DMGuenther  JMMorton  DL Lymphatic mapping and sentinel lymphadenectomy for breast cancer.  Ann Surg 1994;220 (3) 391- 401PubMedGoogle ScholarCrossref
2.
Grube  BJGiuliano  AE The current role of sentinel node biopsy in the treatment of breast cancer.  Adv Surg 2004;38121- 166PubMedGoogle Scholar
3.
Lyman  GHGiuliano  AESomerfield  MR  et al. American Society of Clinical Oncology, American Society of Clinical Oncology Guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.  J Clin Oncol 2005;23 (30) 7703- 7720PubMedGoogle ScholarCrossref
4.
Sabel  MSZhang  PBarnwell  JMWinston  JSHurd  TCEdge  SB Accuracy of sentinel node biopsy in predicting nodal status in patients with breast carcinoma.  J Surg Oncol 2001;77 (4) 243- 246PubMedGoogle ScholarCrossref
5.
Stitzenberg  KBCalvo  BFIacocca  MV  et al.  Cytokeratin immunohistochemical validation of the sentinel node hypothesis in patients with breast cancer.  Am J Clin Pathol 2002;117 (5) 729- 737PubMedGoogle Scholar
6.
Turner  RROllila  DWKrasne  DLGiuliano  AE Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma.  Ann Surg 1997;226 (3) 271- 276PubMedGoogle ScholarCrossref
7.
Weaver  DLKrag  DNHarlow  SPO’Connell  M Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma.  Cancer 2000;88 (5) 1099- 1107PubMedGoogle ScholarCrossref
8.
Bear  HDAnderson  SSmith  RE  et al.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Breast and Bowel Project Protocol B-27.  J Clin Oncol 2006;24 (13) 2019- 2027PubMedGoogle ScholarCrossref
9.
Mauri  DPavlidis  NIoannidis  JP Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.  J Natl Cancer Inst 2005;97 (3) 188- 194PubMedGoogle ScholarCrossref
10.
Kuerer  HMNewman  LASmith  TL  et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.  J Clin Oncol 1999;17 (2) 460- 469PubMedGoogle Scholar
11.
Kuerer  HMSahin  AHunt  KK  et al.  Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.  Ann Surg 1999;230 (1) 72- 78PubMedGoogle ScholarCrossref
12.
Kuerer  HMHunt  KKNewman  LARoss  MIAmes  FCSingletary  SE Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues.  J Am Coll Surg 2000;190 (3) 350- 363PubMedGoogle ScholarCrossref
13.
Veronesi  UPaganellli  GViale  G  et al.  Sentinel-lymph node biopsy as a staging procedure in breast cancer: update of a randomised controlled study.  Lancet Oncol 2006;7 (12) 983- 990PubMedGoogle ScholarCrossref
14.
Harris  LNKaelin  CMBellow  JRWiner  ER Preoperative therapy for operable breast cancer. Harris  JRLippman  MEMorrow  M Disease of the Breast. 3rd ed. Philadelphia, PA Lippincott Williams & Wilkins2004;929- 943Google Scholar
15.
Fisher  BBryant  JWolmark  N  et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.  J Clin Oncol 1998;16 (8) 2672- 2685PubMedGoogle Scholar
16.
Breslin  TMCohen  LSahin  A  et al.  Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.  J Clin Oncol 2000;18 (20) 3480- 3486PubMedGoogle Scholar
17.
Nason  KSAnderson  BOByrd  DR  et al.  Increased false negative sentinel node rates after preoperative chemotherapy for invasive breast carcinoma.  Cancer 2000;89 (11) 2187- 2194PubMedGoogle ScholarCrossref
18.
Cohen  LFBreslin  TMKuerer  HMRoss  MIHunt  KKSahin  AA Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy.  Am J Surg Pathol 2000;24 (9) 1266- 1272PubMedGoogle ScholarCrossref
19.
Tafra  LVerbanac  KMLannin  DR Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer.  Am J Surg 2001;182 (4) 312- 315PubMedGoogle ScholarCrossref
20.
Haid  ATausch  CLang  A  et al.  Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma?  Cancer 2001;92 (5) 1080- 1084PubMedGoogle ScholarCrossref
21.
Fernández  ACortés  MBenito  E  et al.  Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy.  Nucl Med Commun 2001;22 (4) 361- 366PubMedGoogle ScholarCrossref
22.
Miller  ARThomason  VEYeh  I-T  et al.  Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma.  Ann Surg Oncol 2002;9 (3) 243- 247PubMedGoogle ScholarCrossref
23.
Stearns  VEwing  CASlack  RPenannen  MFHayes  DFTsangaris  TN Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla for inflammatory breast cancer.  Ann Surg Oncol 2002;9 (3) 235- 242PubMedGoogle ScholarCrossref
24.
Brady  EW Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer.  Breast J 2002;8 (2) 97- 100PubMedGoogle ScholarCrossref
25.
Julian  TBDusi  DWolmark  N Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer.  Am J Surg 2002;184 (4) 315- 317PubMedGoogle ScholarCrossref
26.
Piato  JRMBarros  ACSDPincerato  KMSampaio  APQPinotti  JA Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy: a pilot study.  Eur J Surg Oncol 2003;29 (2) 118- 120PubMedGoogle ScholarCrossref
27.
Schwartz  GFMeltzer  AJ Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast.  Breast J 2003;9 (5) 374- 379PubMedGoogle ScholarCrossref
28.
Balch  GCMithani  SKRichards  KRBeauchamp  RDKelley  MC Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer.  Ann Surg Oncol 2003;10 (6) 616- 621PubMedGoogle ScholarCrossref
29.
Mamounas  EP Sentinel lymph node biopsy after neoadjuvant systemic therapy.  Surg Clin North Am 2003;83 (4) 931- 942PubMedGoogle ScholarCrossref
30.
Reitsamer  RPeintinger  FRettenbacvher  LProkop  E Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.  J Surg Oncol 2003;84 (2) 63- 67PubMedGoogle ScholarCrossref
31.
Patel  NAPiper  GPatel  JAMalay  MBJulian  TB Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer.  Am Surg 2004;70 (8) 696- 700PubMedGoogle Scholar
32.
Lang  JEEsserman  LJEwing  CA  et al.  Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation.  J Am Coll Surg 2004;199 (6) 856- 862PubMedGoogle ScholarCrossref
33.
Jones  JLZabicki  KChristian  RL  et al.  A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important.  Am J Surg 2005;190 (4) 517- 520PubMedGoogle ScholarCrossref
34.
Shen  JGilcrease  MZBabiera  GV  et al.  Feasibility and accuracy of sentinel lymph nodes biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.  Cancer 2007;109 (7) 1255- 1263PubMedGoogle ScholarCrossref
35.
Newman  EASabel  MSNees  AV  et al.  Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation.  Ann Surg Oncol 2007;14 (10) 2946- 2952PubMedGoogle ScholarCrossref
36.
Lee  SKim  EYKang  SH  et al.  Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients.  Breast Cancer Res Treat 2007;102 (3) 283- 288PubMedGoogle ScholarCrossref
37.
Kinoshita  T Sentinel lymph node biopsy is feasible for breast cancer patients after neoadjuvant chemotherapy.  Breast Cancer 2007;14 (1) 10- 15PubMedGoogle ScholarCrossref
38.
Greene  F Breast cancer. Greene  FPage  DFleming  I AJCC Cancer Staging Manual. 6th ed. New York, NY Springer-Verlag2002;221- 240Google Scholar
39.
Sabel  MSSchott  AFKleer  CG  et al.  Sentinel node biopsy prior to neoadjuvant chemotherapy.  Am J Surg 2003;186 (2) 102- 105PubMedGoogle ScholarCrossref
40.
Schrenk  PHochreiner  GFridrik  MWayand  W Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer.  Breast J 2003;9 (4) 282- 287PubMedGoogle ScholarCrossref
41.
Ollila  DWNeuman  HBSartor  CCarey  LAKlauber-DeMore  N Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers.  Am J Surg 2005;190 (3) 371- 375PubMedGoogle ScholarCrossref
42.
van Rijk  MCNiewig  OERutgers  EJT  et al.  Sentinel node biopsy before neoadjuvant chemotherapy spares breast cancer patients axillary lymph node dissection.  Ann Surg Oncol 2006;13 (4) 475- 479PubMedGoogle ScholarCrossref
43.
Cox  CECox  JMWhite  LB  et al.  Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.  Ann Surg Oncol 2006;13 (4) 483- 490PubMedGoogle ScholarCrossref
44.
Lannin  DRGrube  BBlack  DMPonn  T Breast tattoos for planning surgery following neoadjuvant chemotherapy.  Am J Surg 2007;194 (4) 518- 520PubMedGoogle ScholarCrossref
45.
Black  DMChristy  CJGrube  BJ  et al.  Intraoperative injection of 99m-technetium sulfur colloide for breast sentinel lymph node biopsy.  Paper presented at: 88th Annual Meeting of the New England Surgical Society September 29, 2007 Burlington, VT
46.
Wong  JHCagle  LAMorton  DL Lymphatic drainage of the skin to a sentinel lymph node in a feline model.  Ann Surg 1991;214 (5) 637- 641PubMedGoogle ScholarCrossref
47.
Borgstein  PJPijpers  RComans  EFvan Diest  PJBoom  RPMeijer  S Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection.  J Am Coll Surg 1998;186 (3) 275- 283PubMedGoogle ScholarCrossref
48.
Krag  DWeaver  DAshikaga  T  et al.  The sentinel node in breast cancer: a multicenter validation study.  N Engl J Med 1998;339 (14) 941- 946PubMedGoogle ScholarCrossref
49.
O’Hea  BJHill  ADEl-Shirbiny  AM  et al.  Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center.  J Am Coll Surg 1998;186 (4) 423- 427PubMedGoogle ScholarCrossref
50.
Chung  MHYe  WGiuliano  AE Role for sentinel lymph node dissection in the management of large (>5 cm) invasive breast cancer.  Ann Surg Oncol 2001;8 (9) 688- 692PubMedGoogle Scholar
51.
Kinoshita  TTakasugi  MIwamoto  EAkashi-Tanaka  SFukutomi  TTerui  S Sentinel lymph node biopsy examination for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy.  Am J Surg 2006;191 (2) 225- 229PubMedGoogle ScholarCrossref
52.
Xing  YFoy  MCox  DDKuerer  HMHunt  KKCormier  JN Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.  Br J Surg 2006;93 (5) 539- 546PubMedGoogle ScholarCrossref
53.
Baslaim  MMAl-Malik  OAAl-Sobhi  SS  et al.  Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy.  Am J Surg 2002;184 (4) 299- 301PubMedGoogle ScholarCrossref
54.
Neuman  HCarey  LAOllila  DW  et al.  Axillary lymph node count is lower after neoadjuvant chemotherapy.  Am J Surg 2006;191 (6) 827- 829PubMedGoogle ScholarCrossref
55.
Tavassoli  FA Pathology of the Breast.  Stamford, CT Appleton & Lange1999;
56.
Sharkey  FEAddington  SLFowler  LJPage  CPCruz  AB Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma.  Mod Pathol 1996;9 (9) 893- 900PubMedGoogle Scholar
57.
Fisher  ERWang  JBryant  JFisher  BMamounas  EWolmark  N Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18.  Cancer 2002;95 (4) 681- 695PubMedGoogle ScholarCrossref
58.
Aktepe  FKapucuoglu  NPak  I The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer.  Histopathology 1996;29 (1) 63- 67PubMedGoogle ScholarCrossref
59.
Tafra  LLannin  DRSwanson  MS  et al.  Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue.  Ann Surg 2001;233 (1) 51- 59PubMedGoogle ScholarCrossref
60.
Symmans  WFPeintinger  FHatzis  C  et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.  J Clin Oncol 2007;25 (28) 4414- 4422PubMedGoogle ScholarCrossref
61.
Ogston  KNMiller  IDHutcheon  AW  et al.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.  Breast 2003;12 (5) 320- 327PubMedGoogle ScholarCrossref
62.
Khan  ASabel  MSNees  AV  et al.  Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy.  Ann Surg Oncol 2005;12 (9) 697- 704PubMedGoogle ScholarCrossref
63.
Mauriac  LMacGrogan  GAvril  A  et al.  Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124 month median follow-up (IBBGS).  Ann Oncol 1999;10 (1) 47- 52PubMedGoogle ScholarCrossref
64.
Grube  BJGiuliano  AE Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial.  Semin Surg Oncol 2001;20 (3) 230- 237PubMedGoogle ScholarCrossref
65.
Lucci  A McCall  LMBeitsch  PD  et al.  Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.  J Clin Oncol 2007;25 (24) 3657- 3663PubMedGoogle ScholarCrossref
66.
Guenther  JMHansen  NMDiFronzo  LA  et al.  Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes.  Arch Surg 2003;138 (1) 52- 56PubMedGoogle ScholarCrossref
67.
Fant  JSGrant  MDKnox  SM  et al.  Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection.  Ann Surg Oncol 2003;10 (2) 126- 130PubMedGoogle ScholarCrossref
68.
Jeruss  JSWinchester  DJSener  SF  et al.  Axillary recurrence after sentinel node biopsy.  Ann Surg Oncol 2005;12 (1) 34- 40PubMedGoogle ScholarCrossref
69.
Hwang  RFGonzalez-Angulo  AMBuchholz  TA  et al.  Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary lymph node dissection.  Cancer 2007;110 (4) 723- 730PubMedGoogle ScholarCrossref
70.
van de Vijver  MJHe  YDvan't Veer  LJ  et al.  A gene-expression signature as a predictor of survival in breast cancer.  N Engl J Med 2002;347 (25) 1999- 2009PubMedGoogle ScholarCrossref
71.
Perou  CMSorlie  TEisen  MB  et al.  Molecular portraits of human breast tumours.  Nature 2000;406 (6797) 747- 752PubMedGoogle ScholarCrossref
72.
Perou  CMJeffrey  SSvan de Rijn  M  et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.  Proc Natl Acad Sci U S A 1999;96 (16) 9212- 9217PubMedGoogle ScholarCrossref
73.
Paik  SShak  STang  G  et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.  N Engl J Med 2004;351 (27) 2817- 2826PubMedGoogle ScholarCrossref
74.
Hayes  DFThor  ADDressler  LG  et al.  Her2 and response to paclitaxel in node-positive breast cancer.  N Engl J Med 2007;357 (15) 1496- 1506PubMedGoogle ScholarCrossref
75.
Huang  EHStrom  EAPerkins  GH  et al.  Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score.  Int J Radiat Oncol Biol Phys 2006;66 (2) 352- 357PubMedGoogle ScholarCrossref
Paper
July 21, 2008

Breast Sentinel Lymph Node Dissection Before Preoperative Chemotherapy

Author Affiliations

Author Affiliations: Departments of Surgery (Drs Grube, Christy, Black, and Lannin), Pathology (Drs Martel and Tavassoli), Medical Oncology (Drs Harris, DiGiovanna, Chung, Abu-Khalaf, and Miller), Therapeutic Radiology (Drs Weidhaas and Higgins), and Radiology Breast Imaging (Dr Philpotts), Yale University School of Medicine, New Haven, Connecticut.

Arch Surg. 2008;143(7):692-700. doi:10.1001/archsurg.143.7.692
Abstract

Hypothesis  Timing of sentinel lymph node dissection (SLND), before or after preoperative chemotherapy (PC), for breast cancer is controversial.

Design  Single-institution experience with SLND before PC.

Setting  Data from prospectively collected Yale-New Haven Breast Center Database.

Patients  Fifty-five SLNDs were performed before PC for invasive breast cancer in clinically node-negative patients between October 1, 2003, and September 30, 2007. The results are compared with patients who underwent SLND and definitive breast and axillary surgery before chemotherapy (control group; n = 463 SLNDs).

Interventions  If sentinel nodes (SNs) were negative before PC, no axillary lymph node dissection (ALND) was performed. If SNs were positive, ALND was performed after PC at the time of definitive breast surgery.

Main Outcome Measures  Sentinel node identification rate, false-negative rate, rate of positivity, and rate of residual disease in axilla.

Results  Of the 55 SLNDs performed before PC, 30 (55%) had a positive SN. The SN identification rate was 100% and the clinical false-negative rate was 0%. In the control group of those with a positive SN, 55% (56 of 101 patients) had no additional positive nodes, 25% (25 of 101) had 1 to 3 positive nodes, and 20% (20 of 101) had 4 or more positive nodes. In the group with a positive SN before PC, 69% (18 of 26 patients) had no additional positive nodes after PC, 27% (7 of 26) had 1 to 3 nodes, and 4% (1 of 26) had 4 or more nodes. Among the SN-positive patients, a pathologic complete response in the breast was found in 4 of 18 patients who had a tumor-free axilla after PC.

Conclusions  Sentinel lymph node dissection before PC allows accurate staging of the axilla for prognosis and treatment decisions. Despite downstaging by PC, a significant percentage of patients had residual nodal disease in the axillary dissection.

×